Cui Feilun, Zhang Yueshi, Fan Yu
Department of Urology, Affiliated Taizhou Second People's Hospital of Yangzhou University, Taizhou, China.
Department of Urology, The Fourth Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Front Pharmacol. 2025 May 6;16:1580705. doi: 10.3389/fphar.2025.1580705. eCollection 2025.
Wu-Zi-Yan-Zong (WZYZ) formula is a traditional Chinese botanical drug that has been used to treat male infertility. This meta-analysis aims to evaluate its effectiveness of the WZYZ formula as an adjuvant therapy for treating abnormal sperm parameters associated with male infertility.
A comprehensive literature search was conducted using PubMed, Embase, Cochrane Library, Web of Science, SinoMed, Wanfang, and CNKI databases until December 12, 2024 to identify randomized controlled trials (RCTs) that assessed the effectiveness of the WZYZ formula as an adjuvant therapy for treating abnormal sperm parameters associated in men with infertility. For dichotomous data, the pooled results were summarized as risk ratio (RR) with 95% confidence intervals (CI), while continuous data were expressed as pooled weighted mean difference (WMD) with 95% CI.
A total of 11 RCTs involving 951 men were identified. The pooled results showed that the WZYZ formula, when combined with control treatment, significantly improved the pregnancy rate of female partners (RR 1.68; 95% CI 1.34-2.11), semen volume (WMD 0.58 mL; 95% CI 0.28-0.89), sperm concentration (WMD 6.87 × 10/mL; 95%CI 4.24-9.51), total sperm motility (WMD 15.55%; 95% CI 10.38-20.72), forward grade (a) sperm motility (WMD 5.44%; 95% CI 1.86-9.01), forward grade (a + b) sperm motility (WMD 7.14%; 95% CI 4.04-10.23), abnormal sperm morphology (WMD -10.38%; 95% CI -15.72 to -5.03), and activity of the acrosome enzyme (WMD 8.02 × 10 μIU; 95% CI 3.58-12.46.
Adjuvant treatment with WZYZ formula significantly improves the pregnancy rate of female partners by improving several semen parameters in infertile men with abnormal sperm parameters. However, further well-designed RCTs with larger sample sizes are necessary to definitively determine the efficacy and safety of the WZYZ formula in treating abnormal sperm parameters associated with male infertility.
五子衍宗方是一种用于治疗男性不育症的传统中药方剂。本荟萃分析旨在评估五子衍宗方作为辅助疗法治疗与男性不育相关的异常精子参数的有效性。
使用PubMed、Embase、Cochrane图书馆、Web of Science、中国生物医学文献数据库、万方数据库和中国知网数据库进行全面的文献检索，直至2024年12月12日，以识别评估五子衍宗方作为辅助疗法治疗男性不育相关异常精子参数有效性的随机对照试验（RCT）。对于二分数据，汇总结果以风险比（RR）及95%置信区间（CI）表示，而连续数据则以汇总加权均数差（WMD）及95%CI表示。
共纳入11项RCT，涉及951名男性。汇总结果显示，五子衍宗方与对照治疗联合使用时，显著提高了女性伴侣的妊娠率（RR 1.68；95%CI 1.34 - 2.11）、精液量（WMD 0.58 mL；95%CI 0.28 - 0.89）、精子浓度（WMD 6.87×10⁶/mL；95%CI 4.24 - 9.51）、精子总活力（WMD 15.55%；95%CI 10.38 - 20.72）、前向运动（a级）精子活力（WMD 5.44%；9S%CI 1.86 - 9.01）、前向运动（a + b级）精子活力（WMD 7.14%；95%CI 4.04 - 10.23）、异常精子形态（WMD -10.38%；95%CI -15.72至 -5.03）和顶体酶活性（WMD 8.02×10³μIU；95%CI 3.58 - 12.46）。
五子衍宗方辅助治疗可通过改善精子参数异常的不育男性的多项精液参数，显著提高女性伴侣的妊娠率。然而，需要进一步设计更完善、样本量更大的RCT来明确五子衍宗方治疗男性不育相关异常精子参数的疗效和安全性。
Zotero 插件
